Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Medeor to Start Late-Stage Clinical Trial of Immunotherapy for Transplant Patients


The personalized therapeutic could replace immune-suppressing drugs in patients who have received an organ transplant.

Share this!

May 1, 2017 | by Sarah Hand, M.Sc.

Medeor Therapeutics has just received the FDA go-ahead to start a clinical trial of its cell-based immunotherapy, MDR-101. The personalized therapeutic could replace immune-suppressing drugs in patients who have received an organ transplant.

Currently, patients who are given a donor organ must take drugs designed to dampen the immune system for the rest of their lives. These drugs can help mitigate the risk of organ rejection, however they carry their own risks.

Over 30,000 people in the US undergo organ transplant surgery each year, however as many as 33 percent of these transplants will be rejected within five years of the procedure. Heart, liver and kidney transplants remain some of the most common procedures, and the need for these vital organs often outweighs the supply.

Immunosuppressive drugs – including cyclosporine and tacrolimus – are effective, however they have also been linked to an increased risk of serious infections, heart disease, diabetes and cancer. For kidney transplant recipients, these drugs can even have damaging effects on the kidneys, thereby potentially harming the transplanted organ and putting the patient back on the waiting list.

“The current standard of care to prevent rejection of organ transplants is far from optimal due to unacceptably high long-term failure rates and treatment-associated complications, and new approaches are greatly needed to relieve organ transplant recipients from the litany of undesirable effects associated with anti-rejection drug regimens,” said Dr. Scott Batty, Jr., chief medical officer of Medeor. “MDR-101 has the potential to address the two most critical transplant patient needs: preventing organ rejection and mitigating anti-rejection treatment-associated toxicities.”

Not only will the FDA allow Medeor to start trials of their investigational new drug, but the company will also be permitted to jump directly into Phase III with living donor kidney transplants. This is thanks to a Special Protocol Assessment, which means the FDA has signed off on the company’s protocol design and endpoints.

MDR-101 is a cellular immunotherapy designed to promote the existence of blood and immune cells from both the donor and the recipient in the transplant patient. The drug is designed to stimulate a donor-specific immune tolerance so that the body recognizes the biological signature of the transplant organ, thereby reducing the risk of rejection.

A Phase I clinical trial was used to test MDR-101 in HLA-matched donor organs, however this case only occurs when a close relative – such as a sibling – is able to donate an organ. The immunotherapy may improve outcomes for patients who receive organ transplants that aren’t an exact HLA match, potentially increasing the number of people who could effectively be donors.

The clinical trial is set to begin in the second half of this year, and FDA approval of the immunotherapy will be contingent upon the safety and efficacy data generated during this study. The technology was developed by researchers at Stanford University, for which Medeor holds exclusive worldwide licenses.

Keywords:  Clinical Trial, Immunotherapy, Organ Transplant


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.